Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo

International Journal of Oncology

Volumn 46, Issue 5, 2015, Pages 2172-2180

  Fujihara, Shintaro ^a   Kato, Kiyohito ^a   Morishita, Asahiro ^a   Iwama, Hisakazu ^a   Nishioka, Tomoko ^a   Chiyo, Taiga ^a   Nishiyama, Noriko ^a   Miyoshi, Hisaki ^a   Kobayashi, Mitsuyoshi ^a   Kobara, Hideki ^a   Mori, Hirohito ^a   Okano, Keichi ^a   Suzuki, Yasuyuki ^a   Masaki, Tsutomu ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Cell cycle; Cyclin D1; Epidermal growth factor receptor; Esophageal adenocarcinoma; Metformin; MicroRNAs

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN G1; EPIDERMAL GROWTH FACTOR RECEPTOR; METFORMIN; MICRORNA; RETINOBLASTOMA PROTEIN; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; VASCULOTROPIN; ANTIDIABETIC AGENT; ANTINEOPLASTIC AGENT;

ANGIOGENESIS; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGEAL ADENOCARCINOMA; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR CELL LINE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ADENOCARCINOMA; ANIMAL; DISEASE MODEL; DNA MICROARRAY; DRUG EFFECTS; DRUG SCREENING; ESOPHAGUS TUMOR; FLOW CYTOMETRY; NUDE MOUSE; PATHOLOGY; WESTERN BLOTTING;

ADENOCARCINOMA; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN; MICE; MICE, NUDE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84925435432     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2903     Document Type: Article

References (43)

1. Pennathur A, Gibson MK, Jobe BA and Luketich JD: Oesophageal carcinoma. Lancet 381: 400-412, 2013.
2. Enzinger PC and Mayer RJ: Esophageal cancer. N Engl J Med 349: 2241-2252, 2003.
3. Pennathur A, Farkas A, Krasinskas AM, Ferson PF, Gooding WE, Gibson MK, Schuchert MJ, Landreneau RJ and Luketich JD: Esophagectomy for T1 esophageal cancer: Outcomes in 100 patients and implications for endoscopic therapy. Ann Thorac Surg 87: 1048-1055, 2009.
4. Edgren G, Adami HO, Weiderpass E and Nyrén O: A global assessment of the oesophageal adenocarcinoma epidemic. Gut 62: 1406-1414, 2013.
5. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y and Bost F: The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576-3586, 2008.
6. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD and Evans JM: New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625, 2009.
7. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO and Bilo HJ: Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33: 322-326, 2010.
8. Kourelis TV and Siegel RD: Metformin and cancer: New applications for an old drug. Med Oncol 29: 1314-1327, 2012.
9. Anisimov VN, Egormin PA, Piskunova TS, Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV, Karkach AS and Romanyukha AA: Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo. Cell Cycle 9: 188-197, 2010.
10. Zhou XZ, Xue YM, Zhu B and Sha JP: Effects of metformin on proliferation of human colon carcinoma cell line SW-480. Nan Fang Yi Ke Da Xue Xue Bao 30: 1935-1938, 1942, 2010 (In Chinese).
11. Kato K, Gong J, Iwama H, et al: The antidiabetic drug metformin inhibits gastric cancer cell proliferation in vitro and in vivo. Mol Cancer Ther 11: 549-560, 2012.
12. Kobayashi M, Kato K, Iwama H, et al: Antitumor effect of metformin in esophageal cancer: In vitro study. Int J Oncol 42: 517-524, 2013.
13. Miyoshi H, Kato K, Iwama H, et al: Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol 45: 322-332, 2014.
14. Masaki T, Tokuda M, Yoshida S, et al: Comparison study of the expressions of myristoylated alanine-rich C kinase substrate in hepatocellular carcinoma, liver cirrhosis, chronic hepatitis, and normal liver. Int J Oncol 26: 661-671, 2005.
15. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
16. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685, 1970.
17. Towbin H, Staehelin T and Gordon J: Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: Procedure and some applications. Proc Natl Acad Sci USA 76: 4350-4354, 1979.
18. D'Incalci M, Colombo T, Ubezio P, et al: The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 39: 1920-1926, 2003.
19. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
20. Bird-Lieberman EL and Fitzgerald RC: Early diagnosis of oesophageal cancer. Br J Cancer 101: 1-6, 2009.
21. Solaymani-Dodaran M, Logan RF, West J, Card T and Coupland C: Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 53: 1070-1074, 2004.
22. Falk GW: Barrett's esophagus. Gastroenterology 122: 1569-1591, 2002.
23. Fujihara S, Mori H, Kobara H, Nishiyama N, Kobayashi M, Oryu M and Masaki T: Metabolic syndrome, obesity, and gastrointestinal cancer. Gastroenterol Res Pract 2012: 483623, 2012.
24. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 8: 909-915, 2009.
25. Vazquez-Martin A, Oliveras-Ferraros C and Menendez JA: The antidiabetic drug metformin suppresses HER2 (erbB-2) oncoprotein overexpression via inhibition of the mTOR effector p70S6K1 in human breast carcinoma cells. Cell Cycle 8: 88-96, 2009.
26. Vázquez-Martín A, Oliveras-Ferraros C, del Barco S, Martín-Castillo B and Menéndez JA: mTOR inhibitors and the anti-diabetic biguanide metformin: New insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb). Clin Transl Oncol 11: 455-459, 2009.
27. Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F and Nicolucci A: Metformin therapy and risk of cancer in patients with type 2 diabetes: Systematic review. PLoS One 8: e71583, 2013.
28. Masaki T, Shiratori Y, Rengifo W, et al: Cyclins and cyclindependent kinases: Comparative study of hepatocellular carcinoma versus cirrhosis. Hepatology 37: 534-543, 2003.
29. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE and Thor AD: Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8: 2031-2040, 2009.
30. Han S, Kim HY, Park K, Lee MS, Kim HJ and Kim YD: Expression of p27Kip1 and cyclin D1 proteins is inversely correlated and is associated with poor clinical outcome in human gastric cancer. J Surg Oncol 71: 147-154, 1999.
31. Aoyagi K, Koufuji K, Yano S, Murakami N, Terasaki Y, Yamasaki Y, Takeda J, Tanaka M and Shirouzu K: Immunohistochemical study on the expression of cyclin D1 and E in gastric cancer. Kurume Med J 47: 199-203, 2000.
32. Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Martin-Castillo B and Menendez JA: Metformin activates an ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damagelike response. Cell Cycle 10: 1499-1501, 2011.
33. Wang LW, Li ZS, Zou DW, Jin ZD, Gao J and Xu GM: Metformin induces apoptosis of pancreatic cancer cells. World J Gastroenterol 14: 7192-7198, 2008.
34. Ren M, Zhong X, Ma CY, Sun Y, Guan QB, Cui B, Guo J, Wang H, Gao L and Zhao JJ: Insulin-like growth factor-1 promotes cell cycle progression via upregulation of cyclin D1 expression through the phosphatidylinositol 3-kinase/nuclear factor-kappaB signaling pathway in FRTL thyroid cells. Acta Pharmacol Sin 30: 113-119, 2009.
35. Pollak M: Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928, 2008.
36. Zeng ZS, Cohen AM, Zhang ZF, Stetler-Stevenson W and Guillem JG: Elevated tissue inhibitor of metalloproteinase 1 RNA in colorectal cancer stroma correlates with lymph node and distant metastases. Clin Cancer Res 1: 899-906, 1995.
37. Mori M, Mimori K, Sadanaga N, Inoue H, Tanaka Y, Mafune K, Ueo H and Barnard GF: Prognostic impact of tissue inhibitor of matrix metalloproteinase-1 in esophageal carcinoma. Int J Cancer 88: 575-578, 2000.
38. Zhang Y, Liao JM, Zeng SX and Lu H: p53 downregulates Down syndrome-associated DYRK1A through miR-1246. EMBO Rep 12: 811-817, 2011.
39. Takeshita N, Hoshino I, Mori M, et al: Serum microRNA expression profile: miR-1246 as a novel diagnostic and prognostic biomarker for oesophageal squamous cell carcinoma. Br J Cancer 108: 644-652, 2013.
40. Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K and Kuroda M: Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS One 4: e5532, 2009.
41. Liu H, Zhu L, Liu B, Yang L, Meng X, Zhang W, Ma Y and Xiao H: Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett 316: 196-203, 2012.
42. Carmeliet P: VEGF as a key mediator of angiogenesis in cancer. Oncology 69 (Suppl 3): 4-10, 2005.
43. Chen M, Cai E, Huang J, Yu P and Li K: Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: A systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 21: 1126-1134, 2012.